Navigation Links
Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
Date:5/15/2008

could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, VANTAS and SUPPRELIN LA; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; need for additional funds and corporate partners, including for the development of our products; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; difficulties in managing our growth; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. Indevus undertakes no obligati
'/>"/>
SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Allergan as New Partner for SANCTURA Brand
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
5. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
6. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
7. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , ... July 31, 2015 , ... ... competitive market analysis and premium industry insights on the global resorcinol industry. The ... a collective study of vivid market scenarios and analysis of primary and secondary ...
(Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to announce that it ... Fair to be held August 5-9 in Marshall. The Ralco Enrichment Center is an ... and how agriculture impacts their daily lives. This unique exhibit also features a birthing ...
(Date:7/30/2015)... Dallas, TX, USA (PRWEB) , ... July 30, ... ... nano and microsystems, has appointed Francois Vieillard as Sales & Marketing Director. ... executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ business development activities ...
(Date:7/30/2015)... Diego , CA (PRWEB) , ... July 30, ... ... announced the successful completion of a field clinical study of its canine osteoarthritis ... developed together with Aratana Therapeutics (Kansas City, KS) and will be marketed in ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3
... 2 to 3 children in 100 are born with a ... but in 80% of the cases scientists do not know ... Katholieke Universiteit Leuven, in collaboration with an Australian research team, ... mental retardation is caused by a twofold production of two ...
... Jan. 24 Cardica, Inc.,(Nasdaq: CRDC ) ... fiscal 2008 second quarter and six months ended ... excellent commercial progress, with over 1,000,C-Port systems shipped ... an expanding,product line designed to enable minimally-invasive cardiac ...
... Defined Structure Synthesized,in the Lab, Team Completes Second ... ROCKVILLE, Md., Jan. 24 A team of 17,researchers ... the largest,man-made DNA structure by synthesizing and assembling the ... This work, published,online today in the journal Science by ...
Cached Biology Technology:Discovery of new cause of mental retardation simplifies search for treatments 2Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 2Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 3Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 4Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 5Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 6Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 7Venter Institute Scientists Create First Synthetic Bacterial Genome 2Venter Institute Scientists Create First Synthetic Bacterial Genome 3Venter Institute Scientists Create First Synthetic Bacterial Genome 4Venter Institute Scientists Create First Synthetic Bacterial Genome 5Venter Institute Scientists Create First Synthetic Bacterial Genome 6
(Date:7/31/2015)... -- Den 10. internationale konference om Genomik (ICG-10, ... 25. oktober i Shenzhen , Kina. ... år. Siden starten i 2006 er ICB blevet en ... er en af de mest dynamiske, entusiastiske og sjove ... gennembrud og fremskridt inden for ,omik,-forskning, som yderligere vil ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 ... sobre Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 ... . La conferencia celebra su décimo ... se ha convertido en una de las reuniones anuales ... ,ómicas, y es una de las conferencias científicas más ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julho de 2015 ... Genômica (ICG-10, www.icg-10.org ) será realizada pela BGI de ... China . A conferência está ... inauguração em 2006, a ICG se tornou uma das ... e um dos encontros científicos mais dinâmicos, entusiastas e ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... plants supplement the meager diet available from the nutrient-poor ... insects and other small arthropods. Pitcher plants of the ... a simple passive trap but in a paper in ... a biologist and a physicist from the CNRS, working ...
... University center that aims to improve crop production by ... of continued and expanded support from the Monsanto Company, ... will fund student exchanges and a series of plant ... for Plant Molecular Genetics and Agrobiotechnology , a multidisciplinary ...
... emissions from using coal are set to double by 2030, ... global climate change. In view of the essential role of ... where coal is used. The British Geological Survey ... Phase 1 study in Beijing, China today. The aim of this ...
Cached Biology News:Carnivorous plants use pitchers of 'slimy saliva' to catch their prey 2Monsanto expands sponsorship for Peking-Yale Joint Agrobiotechnology Center 2UK scientists lead China closer to carbon capture and storage 2
carnitine deficiency-associated gene expressed in ventricle 1...
HSV 1 IgG...
... R&D Systems adds two new Stem Cell ... stem cell products. The Human Embryonic Stem ... contains the antibodies against: alkaline phosphatase, Nanog, ... Stem Cell Marker Antibody Panel Plus (Catalog ...
... Printing Surface (3 glass slides coated with 100 /500/1000 ... wafer coated with 1000 Angstroms of Gold over TI ... (3 PDMS micropatterned stamps with series of 100 / ... or 200 um x 10 mm lines, 3 PDMS ...
Biology Products: